316P - The effects of axillary lymph node dissection for clinically node negative breast cancer patients

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Breast Cancer, Early Stage
Surgery and/or Radiotherapy of Cancer
Presenter Qiuning Zhang
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors Q. Zhang1, X. Wang2, S. Yang3, Z. Zhang4, B. Lu5, S. Wei2, R. Liu2, B. Zhang3, H. Luo2
  • 1Oncology, Gansu Tumor Hospital, 730050 - Lanzhou/CN
  • 2Radiation Oncology, Gansu Tumor Hospital, 730050 - Lanzhou/CN
  • 3Breast Surgery, Gansu Tumor Hospital, 730050 - Lanzhou/CN
  • 4Oncology, The First Clinical Medical College of Lanzhou University, lanzhou/CN
  • 5Radiation Oncology, Guiyang Tumor Hospital, guiyang/CN

Abstract

Aim

The omission of axillary dissection for clinically node negative breast cancer patients has been controversial.To evaluates the survival benefits of axillary dissection versus no axillary dissection for clinically lymph node negative breast cancer patients.

Methods

Comprehensive searches of Pubmed, Embase, ISI Web of Knowledge, and the Cochrane library were conducted to included relevant studies. Study selection, data abstracting, quality assessment, and evidence level evaluations were done by two independent authors. Data was analyzed by Revman software 5.0.

Results

Five studies were included. There were not any statistical differences in DFS (HR 1.37, 95%CI 0.91-2.07, I2 = 34%), OS (HR 1.29, 95%CI 0.93-1.79, I2 = 34%), local recurrence (RR 1.12, 95%CI 0.77-1.64, I2 = 0%), distant recurrence (RR 1.19, 95%CI 0.91-1.56, I2 = 0%), contralateral breast recurrence (RR 0.57, 95%CI 0.31-1.07, I2 = 0%), death (RR 0.85, 95%CI 0.57-1.26, I2 = 12%) and death from breast cancer (RR 0.56, 95%CI 0.21-.50, I2 = 0%). However, there were significant differences in axillary recurrence (RR 0.15, 95%CI 0.05-0.48, I2 = 0%) and lymphedema (RR 9.63, 95%CI 3.17-29.29, I2 = 0%).

Conclusions

Axillary dissection did not confer a survival benefit nor prevent further nodal relapses in the setting of clinically lymph node negative breast cancer.

Disclosure

All authors have declared no conflicts of interest.